CD274 and renal cell carcinoma: Since 2014, PD-1/PD-L1 inhibitors, especially nivolumab, became an established treatment option for a number of tumors, including melanoma [2], non-small cell lung cancer (NSCLC) [3], renal cell carcinoma (RCC) [4] and Hodgkin’s lymphoma [5].